On paper, biosimilars have great potential to cut development costs, expand patient access to biologics, and improve affordability. The practical reality is that these goals are difficult to achieve.

Pharmacy benefit managers received substantial attention during 2024. Congress and regulating agencies including the FTC and HHS scrutinized PBM business practices and related profits. As a new ...

After inking and expanding a biosimilar production partnership with Pfizer this summer, Korea’s Samsung Biologics is boosting yet another Big Pharma manufacturing agreement. Monday, Samsung said it ...

(MENAFN- EIN Presswire) EINPresswire/ -- The biosimilar contract manufacturing industry has witnessed rapid expansion recently, driven by multiple factors influencing the biopharmaceutical landscape.

In the United States, where around 8 million people rely on insulin for diabetes management, soaring prices have created barriers to accessibility. As Congress takes initial steps to cap monthly ...

Research and Markets has announced the addition of the "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design" report to ...

Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1] Intended acquisition would ...

Providers and patients who want to understand biosimilars can now navigate through a new web app, that was created by Prime, and delivered in partnership with the AMCP Foundation and Biosimilars ...